Annual Current Liabilities
$2.02 M
-$482.00 K-19.26%
December 31, 2023
Summary
- As of February 7, 2025, CANF annual total current liabilities is $2.02 million, with the most recent change of -$482.00 thousand (-19.26%) on December 31, 2023.
- During the last 3 years, CANF annual current liabilities has risen by +$751.00 thousand (+59.18%).
- CANF annual current liabilities is now -38.25% below its all-time high of $3.27 million, reached on December 31, 2019.
Performance
CANF Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$1.99 M
-$33.00 K-1.63%
June 30, 2024
Summary
- As of February 7, 2025, CANF quarterly total current liabilities is $1.99 million, with the most recent change of -$33.00 thousand (-1.63%) on June 30, 2024.
- Over the past year, CANF quarterly current liabilities has dropped by -$246.00 thousand (-11.02%).
- CANF quarterly current liabilities is now -49.29% below its all-time high of $3.92 million, reached on June 30, 2019.
Performance
CANF Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
CANF Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -19.3% | -11.0% |
| 3 y3 years | +59.2% | -15.8% |
| 5 y5 years | -35.2% | -49.3% |
CANF Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -26.0% | at low | -31.6% | at low |
| 5 y | 5-year | -38.3% | +59.2% | -39.3% | +56.6% |
| alltime | all time | -38.3% | +59.2% | -49.3% | +83.1% |
Can-Fite BioPharma Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2024 | - | $1.99 M(-1.6%) |
| Dec 2023 | $2.02 M(-19.3%) | $2.02 M(-8.6%) |
| Sep 2023 | - | $2.21 M(-1.0%) |
| Jun 2023 | - | $2.23 M(-22.8%) |
| Mar 2023 | - | $2.89 M(+15.5%) |
| Dec 2022 | $2.50 M(-8.4%) | $2.50 M(-10.5%) |
| Sep 2022 | - | $2.80 M(+29.9%) |
| Jun 2022 | - | $2.15 M(-25.9%) |
| Mar 2022 | - | $2.90 M(+6.4%) |
| Dec 2021 | $2.73 M(+115.1%) | $2.73 M(+26.8%) |
| Sep 2021 | - | $2.15 M(-8.7%) |
| Jun 2021 | - | $2.36 M(+14.6%) |
| Mar 2021 | - | $2.06 M(+62.3%) |
| Dec 2020 | $1.27 M(-61.2%) | $1.27 M(-30.2%) |
| Sep 2020 | - | $1.82 M(+21.2%) |
| Jun 2020 | - | $1.50 M(-54.1%) |
| Dec 2019 | $3.27 M(+4.9%) | - |
| Dec 2019 | - | $3.27 M(+4.7%) |
| Sep 2019 | - | $3.13 M(-20.2%) |
| Jun 2019 | - | $3.92 M(+44.8%) |
| Mar 2019 | - | $2.71 M(-13.3%) |
| Dec 2018 | $3.12 M(+77.8%) | - |
| Dec 2018 | - | $3.12 M(+32.1%) |
| Sep 2018 | - | $2.36 M(+9.5%) |
| Jun 2018 | - | $2.16 M(-15.3%) |
| Mar 2018 | - | $2.55 M(+45.2%) |
| Dec 2017 | $1.75 M | - |
| Dec 2017 | - | $1.75 M(+27.0%) |
| Sep 2017 | - | $1.38 M(-13.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $1.59 M(-16.9%) |
| Mar 2017 | - | $1.92 M(-23.3%) |
| Dec 2016 | $2.50 M(+40.8%) | - |
| Dec 2016 | - | $2.50 M(+55.1%) |
| Sep 2016 | - | $1.61 M(+1.1%) |
| Jun 2016 | - | $1.60 M(-22.8%) |
| Mar 2016 | - | $2.07 M(+16.3%) |
| Dec 2015 | $1.78 M(+19.9%) | - |
| Dec 2015 | - | $1.78 M(+23.4%) |
| Sep 2015 | - | $1.44 M(+2.8%) |
| Jun 2015 | - | $1.40 M(-43.4%) |
| Mar 2015 | - | $2.48 M(+67.0%) |
| Dec 2014 | $1.48 M(-30.7%) | - |
| Dec 2014 | - | $1.48 M(+1.3%) |
| Sep 2014 | - | $1.46 M(+13.5%) |
| Jun 2014 | - | $1.29 M(-17.3%) |
| Mar 2014 | - | $1.56 M(-27.1%) |
| Dec 2013 | $2.14 M(-8.0%) | $2.14 M(+47.8%) |
| Sep 2013 | - | $1.45 M(-9.6%) |
| Jun 2013 | - | $1.60 M(-4.0%) |
| Mar 2013 | - | $1.67 M(-28.3%) |
| Dec 2012 | $2.33 M(+71.8%) | - |
| Dec 2012 | - | $2.33 M(+82.5%) |
| Sep 2012 | - | $1.27 M(+13.9%) |
| Jun 2012 | - | $1.12 M(-24.8%) |
| Mar 2012 | - | $1.49 M(+9.9%) |
| Dec 2011 | $1.35 M | - |
| Dec 2011 | - | $1.35 M(+24.7%) |
| Sep 2011 | - | $1.09 M |
FAQ
- What is Can-Fite BioPharma annual total current liabilities?
- What is the all time high annual current liabilities for Can-Fite BioPharma?
- What is Can-Fite BioPharma annual current liabilities year-on-year change?
- What is Can-Fite BioPharma quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Can-Fite BioPharma?
- What is Can-Fite BioPharma quarterly current liabilities year-on-year change?
What is Can-Fite BioPharma annual total current liabilities?
The current annual current liabilities of CANF is $2.02 M
What is the all time high annual current liabilities for Can-Fite BioPharma?
Can-Fite BioPharma all-time high annual total current liabilities is $3.27 M
What is Can-Fite BioPharma annual current liabilities year-on-year change?
Over the past year, CANF annual total current liabilities has changed by -$482.00 K (-19.26%)
What is Can-Fite BioPharma quarterly total current liabilities?
The current quarterly current liabilities of CANF is $1.99 M
What is the all time high quarterly current liabilities for Can-Fite BioPharma?
Can-Fite BioPharma all-time high quarterly total current liabilities is $3.92 M
What is Can-Fite BioPharma quarterly current liabilities year-on-year change?
Over the past year, CANF quarterly total current liabilities has changed by -$246.00 K (-11.02%)